RN Expertise, Inc. v. United States

97 Fed. Cl. 460, 2011 WL 879730
CourtUnited States Court of Federal Claims
DecidedMarch 11, 2011
DocketNo. 09-673C
StatusPublished
Cited by11 cases

This text of 97 Fed. Cl. 460 (RN Expertise, Inc. v. United States) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
RN Expertise, Inc. v. United States, 97 Fed. Cl. 460, 2011 WL 879730 (uscfc 2011).

Opinion

OPINION AND ORDER

DAMICH, Judge.

This bid protest case is before the Court on the parties’ cross-motions for judgment on the administrative record related to the Plaintiffs claims concerning the procurement of urine collection services for the Department of the Navy’s drug testing program. The Plaintiff, RN Expertise, Inc., was the presumptive awardee when the Department of the Navy decided to cancel its solicitation and acquire collection services via an inter-agency agreement between the Department of Defense and the Department of the Interi- or. The Plaintiff contends that the Department of the Navy’s cancellation decision was arbitrary, capricious, and in violation of procurement law. The Plaintiff also challenges the interagency agreement and another, later contract between the Department of Defense and Pembrooke Occupational Health, Inc., entered into for drug testing services, as violating federal statutes and procurement regulations.2

For the reasons stated below, the Court finds that the Department of the Navy’s decision to cancel the solicitation was not arbitrary, capricious, or in violation of procurement law. The Court also finds that the Plaintiff has failed to meet its burden of proving that the Department of Defense’s actions were clear and prejudicial violations of procurement law. Accordingly, the Court DENIES Plaintiffs motion for judgment on the administrative record and GRANTS the ■Defendant’s cross-motion for judgment on the administrative record.

I. BACKGROUND

A. Factual Background

Each agency in the executive branch of the Federal Government is required to establish a drug testing program. Administrative Record (“AR”) 46. The primary components of the drug testing process include the collection of a urine specimen, laboratory analysis, and medical review officer (MRO) services. AR 591. The issues in this case relate to the Department of the Navy’s (“Navy’s”) cancellation of its solicitation for urine collection services and the Department of Defense’s (“DOD’s”) procurement of urine collection services. Specifically, the DOD’s procurement actions at issue include an interagency agreement (“IAA”) with the Department of the Interior (“DOI”), a solicitation for drug testing services, and a contract with Pem-brooke Occupational Health, Inc. (“Pem-brooke”).

1. The Navy’s Solicitation for Urine Collection Services

From 1993 to 2008, the Navy contracted with BAE Systems Technologies (“BAE”) for its urine collection services. AR 592. After BAE informed the Navy that it would not renew its contract for 2009, the Navy Office of Civilian Human Resources (“OCHR”) submitted a request to Navy’s Fleet Industrial Supply Center (“FISC”) to issue a solicita[464]*464tion for urine collection services for the Navy. AR 3, 592. FISC issued this solicitation, no. N00189-08-R-Z071, on October 6, 2008. AR 171.

According to the solicitation, the Navy’s requirements included (1) collections in the continental United States (“CONUS”), (2) overseas collections (“OCONUS”), (3) pre-employment collections, and (4) reasonable suspicion collections. AR 34-36. The offer-ors were required to provide unit and total pricing for each of the four categories. AR 34-36,175-76.

The solicitation closed on November 12, 2008. AR 171. The Navy, via FISC, received four proposals in response to the solicitation. Id. The Navy selected two of the four offerors, including the Plaintiff, for further discussions. Id. Following these discussions, on December 9, 2008, the two bidders submitted their final offer or response. Id. at 171-72. The Navy contracting officer compared technical and pricing evaluations for the two offerors and determined that the Plaintiffs offer represented the best value, although at a higher price. AR 177. On December 15, 2008, the Navy contracting officer informed the Navy Drug Program Manager (“DPM”) of her recommendation to select the Plaintiff. See AR 586.

2. The Navy’s Decision to Cancel the Solicitation

After the Navy contracting officer determined that the Plaintiffs offer represented the best value, but before a contract was awarded, the Navy DPM requested funding approval from the DOD Tricare Management Agency (“TMA”) — the fund sponsor for DOD drag testing programs. See AR 4, 211, 592. Army Colonel Shippee, of TMA, indicated that the Plaintiffs offer was too expensive and that DOD’s IAA with DOI for drug testing services was a less expensive alternative for the Navy’s urine collection services. AR 592.

Colonel Shippee’s response prompted the Navy DPM to compare the services to be provided under the IAA to the services required under the solicitation with the result that she concluded that “the required services under both instruments were virtually identical.” AR 311. Under the IAA Service Level Agreement, the baseline services included “in-house, on-site, and off-site collections with a nation-wide and international network of collection sites provided through venders.” AR 581. The types of specific tests to be available under the IAA included “pre-employment, random, [and] reasonable suspicion/cause” tests. AR 581. Accordingly, the Navy DPM determined that the Navy’s requirements for worldwide collections, on-site and off-site collections, pre-em-ployment collections, and reasonable suspicion collections could be met through the IAA AR 311.

Under the IAA, the urine collection services could be performed by trained DOI collectors or through DOI’s contract with Pembrooke (“DOI-Pembrooke contract”). AR 593, 603. The cost was the same for the customer whether DOI or Pembrooke provided the services. AR 575-76 (October 2008 IAA), AR 22-23 (December 2008 IAA), AR 593. The contracting officer determined that the collection cost under the IAA for each category of collection (i.e., CONUS, OCO-NUS, pre-employment, and reasonable suspicion) was less than the Plaintiffs offer. AR 211-12.

On December 18, 2008, the Navy DPM notified the contracting officer that “[a]fter reviewing the terms and conditions of the [IAA] ..., it has been determined that it is the most cost efficient to the Department of the Navy.” AR 586. On the same day, FISC issued the amendment to cancel the solicitation. AR 182. FISC’s memorandum to the file, in support of the cancellation decision, indicates that the IAA “will provide urine collection services at a lower cost than the proposals received in response to the solicitation” and “the offers resulting from [the] solicitation do not provide the best value for the Navy.” AR 212.

3. DOD’s Procurement of Urine Collection Services

During the Navy’s solicitation process, but not known to the Navy contracting officer, DOD was deliberating on more cost effective alternatives for its drug testing services, to include urine collection, lab testing, and MRO services. See AR 211. At that time, [465]*465other units within DOD maintained separate IAAs with DOI for such services. AR 599, 604.

DOD determined that it would consolidate and centralize drug testing services beginning in fiscal year 2009 and pursue a competitive procurement. See AR 596, 599-600, 604. TMA notified the United States Army Medical Research Acquisition Activity (“US-AMRAA”) 3 “of its need to procure specimen collection, laboratory analysis, and medical review services.” AR 596.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bannum, Inc. v. United States
Federal Claims, 2021
Per Aarsleff A/S v. United States
123 Fed. Cl. 147 (Federal Claims, 2015)
Savantage Financial Services, Inc. v. United States
123 Fed. Cl. 7 (Federal Claims, 2015)
American Apparel, Inc. v. United States
108 Fed. Cl. 11 (Federal Claims, 2012)
International Genomics Consortium v. United States
104 Fed. Cl. 669 (Federal Claims, 2012)
Distributed Solutions, Inc. v. United States
104 Fed. Cl. 368 (Federal Claims, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
97 Fed. Cl. 460, 2011 WL 879730, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rn-expertise-inc-v-united-states-uscfc-2011.